Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications
Shots:
- The US FDA’s Center for Devices and Radiological Health has granted breakthrough device designation for Shreis’ Cytotron- invented by Dr. Rajah Vijay Kumar in Bengaluru- India- indicated for the treatment of solid tumors of the breast- liver- and pancreas
- Shreis is actively collaborating with other companies for the clinical studies of Cytotron in the proposed indications and plans to submit a request for BT designation in adult and pediatric brain tumors- lung cancer- and other life-limiting diseases
- The Cytotron is intended to cause degeneration of uncontrolled growth of tissues- act by selectively targeting and enabling tissue apoptosis- thus indicated to treat protein linked regenerating disorders like a neoplastic disease
Click here to read full press release/ article | Ref: PRNewswire | Image: Your story
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com